{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+IV%2BOral&page=2", "query": { "intervention": "Dexamethasone IV+Oral", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 388, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+IV%2BOral&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+IV%2BOral&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T08:49:20.286Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05552222", "title": "A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1590, "start_date": "2022-10-25", "completion_date": "2033-10-28", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 67, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552222" }, { "nct_id": "NCT05488847", "title": "Opioid-Free Pain Protocol After Shoulder Arthroplasty", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Shoulder Arthropathy", "Shoulder Pain" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Pregabalin", "type": "DRUG" }, { "name": "Tramadol", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ropivicaine", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Tizanidine", "type": "DRUG" }, { "name": "Magnesium", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Oxycodone Hydrochloride 5 Mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2022-06-25", "completion_date": "2026-09-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05488847" }, { "nct_id": "NCT04052880", "title": "Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Larysa Sanchez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 17, "start_date": "2019-10-24", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04052880" }, { "nct_id": "NCT03412565", "title": "A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2018-04-26", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 16, "location_summary": "Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more", "locations": [ { "city": "Southington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412565" }, { "nct_id": "NCT03571321", "title": "Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "ALL, Childhood", "ALL" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Methotrexate (Intrathecal Administration)", "type": "DRUG" }, { "name": "Methotrexate (Intravenous Administration)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Methotrexate Oral Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 15, "start_date": "2019-05-28", "completion_date": "2027-09-05", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 2, "location_summary": "Chicago, Illinois • Dallas, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03571321" }, { "nct_id": "NCT01038388", "title": "A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-01-15", "completion_date": "2021-08-05", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01038388" }, { "nct_id": "NCT04991103", "title": "Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Amyloidosis" ], "interventions": [ { "name": "DaraVRD/DaraVCD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-09-22", "completion_date": "2028-08-27", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04991103" }, { "nct_id": "NCT02297230", "title": "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Radiation Therapy (RT)", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 44, "start_date": "2002-06", "completion_date": "2014-12-02", "has_results": true, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02297230" }, { "nct_id": "NCT02617277", "title": "Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD1775", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 56, "start_date": "2015-12-28", "completion_date": "2026-02-17", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 3, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02617277" }, { "nct_id": "NCT04407442", "title": "Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2020-11-30", "completion_date": "2023-04-30", "has_results": true, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-10-01T08:49:20.286Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04407442" } ] }